New Managed Care Study Results Reported from University of Houston (Impact of Adjuvant GLP-1RA Treatment on the Adherence of Second-Generation Antipsychotics in Nondiabetic Adults): Managed Care

2026 FEB 25 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Current study results on Managed Care have been published. According to news reporting originating in Houston, Texas, by NewsRx journalists, research stated, “Second-generation antipsychotics (SGA) are well known to frequently cause weight gain, increasing cardiometabolic risk, and reducing medication adherence. Glucagon-like peptide-1 receptor agonists (GLP-1RA) mitigate weight gain in controlled settings, but their real-world impact on SGA adherence remains unexplored.”

The news reporters obtained a quote from the research from the University of Houston, “This study evaluated the role of adjuvant GLP-1RA treatment in improving SGA adherence among nondiabetic adults. A retrospective cohort study using the MarketScan Commercial and Medicaid claims database (2019-2023) identified nondiabetic adult patients initiating GLP-1RA following an SGA prescription, with 60 days overlap between SGA and GLP-1RA prescription fills (Adjuvant GLP-1RA users). Eligible patients were continuously enrolled 90 days pre-GLP-1RA and 180 days post-GLP-1RA initiation (index date). Prescription-time-distribution matching addressed immortal time bias and assigned an index date to SGA-only users. Propensity score matching (PSM) adjusted for baseline covariates. This study identified 2153 eligible patients in the commercial and 787 in the Medicaid subgroups. Compared with SGA-only users, adjuvant GLP-1-RA users achieved a higher mean proportion of days covered (PDC; 74.30% vs 66.91%) and longer persistence (165.6 vs 139.2 d). Medicaid patients showed similar benefits (PDC: 88.25% vs 70.32%; persistence: 162.1 vs 122.1 d). PSM adjusted models demonstrated that the difference in PDC between the study groups was 8.91% (commercial) and 19.80% (Medicaid), with corresponding differences in persistence of 27.12 and 41.21 days. The effect was consistent both when the follow-up period was extended to 365 days and when examined across individual GLP-1RA agents.”

According to the news reporters, the research concluded: “Adjuvant GLP-1RA is associated with improved PDC and adherence to SGA in nondiabetic adults.”

This research has been peer-reviewed.

For more information on this research see: Impact of Adjuvant GLP-1RA Treatment on the Adherence of Second-Generation Antipsychotics in Nondiabetic Adults. Journal of Clinical Psychopharmacology, 2026. Journal of Clinical Psychopharmacology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; Journal of Clinical Psychopharmacology - http://journals.lww.com/psychopharmacology/pages/default.aspx)

Our news correspondents report that additional information may be obtained by contacting Jerusha Daggolu, Dept. of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX. Additional authors for this research include Michael Okonkwo and Hua Chen.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/jcp.0000000000002145. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher of the Journal of Clinical Psychopharmacology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)